PE Ratio
-1.57
₹37.30 -0.15 (-0.40%)
As on October 12, 2026
-11.15%
1 Y CAGR
72
CR
Market Cap
Company profile
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Price Chart
Fundamentals - Company Valuation
PB Ratio
0.20
Dividend Yield
2.31%
Sector PE
47.63
Sector ROE
11.70%
Sector Dividend Yield
0.46%
Financials
LIVE DATA FEED
Total Revenue (YTD)
₹0.7KCAGR 5-Year
-25.50%Peers & Comparison
SUNPHARMA
Sun Pharmaceutical Industries Ltd
Market cap: ₹4,41,477.63 Cr
DIVISLAB
Divi's Laboratories Ltd
Market cap: ₹2,41,576.41 Cr
TORNTPHARM
Torrent Pharmaceuticals Ltd
Market cap: ₹1,82,576.57 Cr
Missed the last rally? Don’t miss the next
Looking for AI-researched technical positive stocks?
Our AI-powered Analytical Portal finds the strongest technical positive stocks with actionable Buy & Sell opportunities.
Corporate Actions
Still Thinking? Not sure which stocks are right for you?
We help investors understand what to buy, when to buy, and why it makes sense for them.
customersupport@jarvisinvest.com
New Customers (Enquiry): +91 7208809638
Mon - Sat | 10:00 AM - 07:00 PM (Sunday Closed)
